Impact of the early reduction of cyclosporine on renal function in heart transplant patients: a French randomised controlled trial

Pascale Boissonnat, Ségolène Gaillard, Catherine Mercier, Michel Redonnet, Bernard Lelong, Marie-Françoise Mattei, Annick Mouly-Bandini, Sabine Pattier, Agnès Sirinelli, Eric Epailly, Shaida Varnous, Marc-Alain Billes, Laurent Sebbag, René Ecochard, Catherine Cornu, François Gueyffier, Pascale Boissonnat, Ségolène Gaillard, Catherine Mercier, Michel Redonnet, Bernard Lelong, Marie-Françoise Mattei, Annick Mouly-Bandini, Sabine Pattier, Agnès Sirinelli, Eric Epailly, Shaida Varnous, Marc-Alain Billes, Laurent Sebbag, René Ecochard, Catherine Cornu, François Gueyffier

Abstract

Background: Using reduced doses of Cyclosporine A immediately after heart transplantation in clinical trials may suggest benefits for renal function by reducing serum creatinine levels without a significant change in clinical endpoints. However, these trials were not sufficiently powered to prove clinical outcomes.

Methods: In a prospective, multicentre, open-label, parallel-group controlled trial, 95 patients aged 18 to 65 years old, undergoing de novo heart transplantation were centrally randomised to receive either a low (130 < trough CsA concentrations <200 μg/L, n = 47) or a standard dose of Cyclosporine A (200 < trough CsA concentrations <300 μg/L, n = 48) for the three first post-transplant months along with mycophenolate mofetil and corticosteroids. Participants had a stable haemodynamic status, a serum creatinine level <250 μmol/L and the donors' cold ischemia time was under six hours; multiorgan transplants were excluded. The change in serum creatinine level over 12 months was used as the main criterion for renal function. Intention-to-treat analysis was performed on the 95 randomised patients and a mixed generalised linear model of covariance was applied.

Results: At 12 months, the mean (± SD) creatinine value was 120.7 μmol/L (± 35.8) in the low-dose group and 132.3 μmol/L (± 49.1) in the standard-dose group (P = 0.162). Post hoc analyses suggested that patients with higher creatinine levels at baseline benefited significantly from the lower Cyclosporine A target. The number of patients with at least one rejection episode was not significantly different but one patient in the low-dose group and six in the standard-dose group required dialysis.

Conclusions: In patients with de novo cardiac transplantation, early Cyclosporine A dose reduction was not associated with renal benefit at 12 months. However, the strategy may benefit patients with high creatinine levels before transplantation.

Trial registration: ClinicalTrials.gov NCT00159159.

Figures

Figure 1
Figure 1
Study flow diagram
Figure 2
Figure 2
Box plot distributions of observed serum creatinine values in standard-dose and low-dose patients by visit (months). Reference horizontal line at 120 μmol/L.

References

    1. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Boucek MM, Novick RJ. The registry of the international society for heart and lung transplantation: fifteenth official report–1998. J Heart Lung Transplant. 1998;17:656–668.
    1. Fritsche. Impact of cyclosporine on the development of immunosuppressive therapy. Transplant Proc. 2003;Suppl 2S:130S–134S.
    1. Taylor DO, Stehlik J, Edwards LB, Aurora P, Christie JD, Dobbels F, Kirk R, Kucheryavaya AY, Rahmel AO, Hertz MI. Registry of the international society for heart and lung transplantation: twenty-sixth official adult heart transplant report-2009. J Heart Lung Transplant. 2009;28:1007–1022. doi: 10.1016/j.healun.2009.08.014.
    1. Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation. 1997;63:664–668. doi: 10.1097/00007890-199703150-00009.
    1. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–940. doi: 10.1056/NEJMoa021744.
    1. Pattison JM, Petersen J, Kuo P, Valantine V, Robbins RC, Theodore J. The incidence of renal failure in one hundred consecutive heart-lung transplant recipients. Am J Kidney Dis. 1995;26:643–648. doi: 10.1016/0272-6386(95)90602-9.
    1. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valantine H. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 1998;66:507–515. doi: 10.1097/00007890-199808270-00016.
    1. Ekberg H, Bernasconi C, Tedesco-Silva H, Vítko S, Hugo C, Demirbas A, Acevedo RR, Grinyó J, Frei U, Vanrenterghem Y, Daloze P, Halloran P. Calcineurin inhibitor minimization in the Symphony study: observational results 3years after transplantation. Am J Transplant. 2009;9:1876–1885. doi: 10.1111/j.1600-6143.2009.02726.x.
    1. Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant. 2009;9:1607–1619. doi: 10.1111/j.1600-6143.2009.02668.x.
    1. Cohen DJ, Vincenti F. A comparative open label study to evaluate graft function in de novo renal allograft recipients treated with reduced dose or standard dose cyclosporine in combination with sirolimus and corticosteroids. Am J Transplant. 2003;Suppl 5:S465.
    1. de Sévaux RG, Gregoor PJ, Hené RJ, Hoitsma AJ, Vos P, Weimar W, Van Gelder T, Hilbrands LB. A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids. J Am Soc Nephrol. 2001;12:1750–1757.
    1. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP. Sirolimus Renal Function Study Group. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation. 2002;74:1560–1567. doi: 10.1097/00007890-200212150-00013.
    1. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation. 1999;68:1526–1532. doi: 10.1097/00007890-199911270-00016.
    1. Muhlbacher F, Paczek L. An open-label study to evaluate the efficacy and safety of cyclosporine reductionin de novo renal allograft recipients receiving sirolimus: a dose comparative study. Am J Transplant. 2002;Supp 3:S238.
    1. Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, Eisen HJ, Salm K, Tolzman D, Gao J, Fitzsimmons W, First R. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006;6:1377–1386. doi: 10.1111/j.1600-6143.2006.01290.x.
    1. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, Andersen CB, Angelini A, Berry GJ, Burke MM, Demetris AJ, Hammond E, Itescu S, Marboe CC, McManus B, Reed EF, Reinsmoen NL, Rodriguez ER, Rose AG, Rose M, Suciu-Focia N, Zeevi A, Billingham ME. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24:1710–1720. doi: 10.1016/j.healun.2005.03.019.
    1. Ekberg H. The use of daclizumab and mycophenolate mofetil in combination with corticosteroids and cyclosporing (low dose versus low dose followed by withdrawal) to optimize renal function in recipients of renal allografts [poster presentation] International Conference of the Transplantation Society (ICTS), Vienna, Austria; 2004.
    1. Agence Nationale d'Accréditation et d'Evaluation en Santé. [Diagnosis of adult chronic kidney failure] Diabetes Metab. 2003;29:315–324. French.
    1. Couchoud C, Pozet N, Labeeuw M, Pouteil-Noble C. Screening early renal failure: cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int. 1999;55:1878–1884. doi: 10.1046/j.1523-1755.1999.00411.x.
    1. van Gelder T. Mycophenolate blood level monitoring: recent progress. Am J Transplant. 2009;9:1495–1499. doi: 10.1111/j.1600-6143.2009.02678.x.
    1. Hertz MI, Aurora P, Benden C, Christie JD, Dobbels F, Edwards LB, Kirk R, Kucheryavaya AY, Rahmel AO, Rowe AW, Stehlik J. Scientific registry of the international society for heart and lung transplantation: introduction to the 2011 annual reports. J Heart Lung Transplant. 2011;30:1071–1132. doi: 10.1016/j.healun.2011.08.002.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅